105882-72-2

Basic information

• Product Name: (2S,6S,7R,8S,9R,10S)-3-Acetyl-9-((2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-7-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-2,6,8,10,12-pentamethyl-4,13-dioxa-bicyclo[8.2.1]tridec-1⁽¹²⁾-en-5-one
• Synonyms: (2S,6S,7R,8S,9R,10S)-3-Acetyl-9-((2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-7-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-2,6,8,10,12-pentamethyl-4,13-dioxa-bicyclo[8.2.1]tridec-1⁽¹²⁾-en-5-one
• CAS NO: 105882-72-2
• Molecular Weight: 655.827
• Mol File: 105882-72-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S,6S,7R,8S,9R,10S)-3-Acetyl-9-((2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-7-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-2,6,8,10,12-pentamethyl-4,13-dioxa-bicyclo[8.2.1]tridec-1⁽¹²⁾-en-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,6S,7R,8S,9R,10S)-3-Acetyl-9-((2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-7-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-2,6,8,10,12-pentamethyl-4,13-dioxa-bicyclo[8.2.1]tridec-1⁽¹²⁾-en-5-one(105882-72-2)
• EPA Substance Registry System: (2S,6S,7R,8S,9R,10S)-3-Acetyl-9-((2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-7-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-2,6,8,10,12-pentamethyl-4,13-dioxa-bicyclo[8.2.1]tridec-1⁽¹²⁾-en-5-one(105882-72-2)

Safety Data

• Hazardous Substances Data: 105882-72-2(Hazardous Substances Data)

Upstream product

• 105882-69-7 pseudoerythromycin A enol ether 

Relevant articles and documents

Translactonization in Erythromycins

When erythromycin A is heated in diethylamine-acetic acid, an erythromycin hemiketal is obtained, which can be further transformed into a new enol ether and spiroketal.The new enol ether is also obtained in equilibrium with the normal one on heating erythromycin A or B in pyridine-acetic acid.The novel compounds, which will be called pseudoerythromycin derivatives, are characterized by a translactonization between the C11-hydroxyl and the lactone group.Their structure was proved by mass and 1H and 13C NMR spectrometry, by acetylation experiments, and by degradation with lead tetraacetate.